Trial · NCT03033511
Adverse events454
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 454
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Placebo | 11 | 373 | 18 |
| other | ANAEMIA | Blood and lymphatic system disorders | Rovalpituzumab Tesirine/Dexamethasone | 45 | 368 | 51 |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Placebo | 10 | 373 | 11 |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Rovalpituzumab Tesirine/Dexamethasone | 31 | 368 | 37 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Placebo | 14 | 373 | 19 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Rovalpituzumab Tesirine/Dexamethasone | 61 | 368 | 79 |
| other | PERICARDIAL EFFUSION | Cardiac disorders | Placebo | 6 | 373 | 7 |
| other | PERICARDIAL EFFUSION | Cardiac disorders | Rovalpituzumab Tesirine/Dexamethasone | 58 | 368 | 63 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Placebo | 14 | 373 | 14 |
| other | ABDOMINAL PAIN | Gastrointestinal disorders | Rovalpituzumab Tesirine/Dexamethasone | 21 | 368 | 24 |
| other | CONSTIPATION | Gastrointestinal disorders | Placebo | 35 | 373 | 37 |
| other | CONSTIPATION | Gastrointestinal disorders | Rovalpituzumab Tesirine/Dexamethasone | 48 | 368 | 57 |
| other | DIARRHOEA | Gastrointestinal disorders | Placebo | 35 | 373 | 39 |
| other | DIARRHOEA | Gastrointestinal disorders | Rovalpituzumab Tesirine/Dexamethasone | 30 | 368 | 35 |
| other | DYSPEPSIA | Gastrointestinal disorders | Placebo | 4 | 373 | 4 |
| other | DYSPEPSIA | Gastrointestinal disorders | Rovalpituzumab Tesirine/Dexamethasone | 20 | 368 | 23 |
| other | NAUSEA | Gastrointestinal disorders | Placebo | 51 | 373 | 56 |
| other | NAUSEA | Gastrointestinal disorders | Rovalpituzumab Tesirine/Dexamethasone | 77 | 368 | 86 |
| other | VOMITING | Gastrointestinal disorders | Placebo | 35 | 373 | 40 |
| other | VOMITING | Gastrointestinal disorders | Rovalpituzumab Tesirine/Dexamethasone | 35 | 368 | 41 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03033511/events